Selectis Health Q2 Shows $8.1M Profit From Asset Sales, But Going Concern Doubt Persists
GBCS has more than doubled off its 52-week low of $0.405 on light trading volume (0.1× avg).
Summary
Selectis Health's Q2 profit of $8.1M came entirely from selling Georgia facilities, not operations. Revenue fell 56%, going concern doubt persists, and two material weaknesses in internal controls were disclosed.
Key Events · Earnings and Guidance · GBCS
-
Q2 Profit Driven Entirely by Asset Sales
Net income of $8.1M for Q2 2026 and $14.6M for the six months came from $19.0M in gains on sale of four Georgia facilities. Loss from operations was $2.1M for the quarter.
-
Healthcare Revenue Down 56%
Healthcare revenue fell to $4.6M in Q2 2026 from $10.4M a year earlier, reflecting the sale of four Georgia facilities in January and May 2026.
-
Going Concern Doubt Persists
Management states substantial doubt exists about the company's ability to continue as a going concern, citing historical losses and projected cash needs despite $7.7M in cash on hand.
-
Two Material Weaknesses Disclosed
The filing discloses two material weaknesses in internal control over financial reporting: one from the 2025 10-K related to lack of formal review processes, and a newly identified one related to complex equity transactions.
Analysis · GBCS · Real Estate & Construction
Selectis Health reported $8.1 million in net income for Q2 2026, but the profit came entirely from selling four Georgia facilities — not from operations. Core healthcare revenue fell 56% year-over-year to $4.6 million, and the company lost $2.1 million from operations. Management states substantial doubt exists about the company's ability to continue as a going concern, and the filing discloses two material weaknesses in internal controls, including a newly identified one related to complex equity transactions. The company also revised prior financial statements to reclassify $401,000 of Series A Preferred Stock from equity to liability after discovering a technical defect under Utah state law. This all comes as Black Pearl Equities' $5.75 per share tender offer is set to expire August 24, 2026 — the same day this report was filed.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GBCS was trading at $5.42 on OTC in the Real Estate & Construction sector, with a market capitalization of approximately $16.6M. The 52-week trading range was $0.41 to $5.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.